Kornimate/medical-research-clean huggingface dataset:
outcome of cardiac arrest survivors

Conditions: Cardiac Arrest Survivors

Summary: early prognosis of cardiac arrest - nearly 40000 new cases per year in france - has been extensively studied, highlighting a poor outcome (less than 8% at hospital discharge). however, little is known on mid and long-term prognostic factors and how these patients do survive from the event. using a regional cohort, the aim of the study is to describe long-term survival rate of cardiac arrest survivors, and to assess the influence of treatment strategies on survival and functional outcome.

the collection of clinical and biological data of patients who experienced cardiac arrest and survive from hospital, including a regular follow-up with qualitative data (functional, neurological and quality of life) may provide important benchmark on the evolution of these patients and on the impact of acute interventions (such as cardio-pulmonary resuscitation, defibrillation, emergent coronary revascularization, neuroprotective treatments). using a large identified cohort of survivors of cardiac arrest, we aim to describe the qualitative long-term prognosis of these cardiac arrest patients (functional, neurological and quality of life status). secondarily, we intend to identify the long-term prognostic factors, and particularly the role of early interventions, using a long-term and qualitative combined endpoint (vital status, functional scales, sf36). this project is observational and will include all patients over 18 admitted alive after non-traumatic cardiac arrest in the area of ile-de-france (france), whatever the cause of the cardiac arrest. patients or their proxies, refusing their participation, will not be included. we will collect all pre- and in-hospital information related to the event and performs prospectively interviews at 3 months and every year anniversary. the questionnaire will include vital status, cardiovascular events, medication and a complete qualitative report (sf36, adl scale, opc, cpc, social-professional activities). this project will provide important data over time on the evolution of these patients. findings will help in measuring the role of different strategies on long-term prognosis and consequently improve the overall management of cardiac arrest.

Eligibility criteria:
inclusion criteria: * patients alive after resuscitation from a out-of-hospital cardiac arrest * all causes for cardiac arrest * age above 18 * informed consent from the patient or next of kin exclusion criteria: * impossibility for communication after hospital discharge, whatever the cause (language, residence...) * follow-up refusal from the patient or next of kin

Keywords: cardiac arrest outcome neurological status
hla-b*5801 screening to prevent allopurinol-induced severe cutaneous adverse reaction

Conditions: Stevens-Johnson Syndrome; Kidney Failure, Chronic

Summary: allopurinol-induced severe cutaneous adverse reaction (scar) is a rare but fatal condition. previous reports have reported that hla-b\*5801 is an important genetic risk factor significantly associated with the development of allopurinol-induced scar. however, there has been no prospective study to prove the clinical efficacy of a hla-b\*5801 screening before administration of allopurinol in predicting allopurinol-induced scar. the purpose of this prospective study is to test our hypothesis that a pre-screening of hla-b\*5801 will significantly reduce the risk of allopurinol-induced scar development compared to the historical control.


Eligibility criteria:
inclusion criteria: * a subject who needs an allopurinol treatment based on the physician's assessement * a subject with chronic kidney disease (ckd) * ckd is diagnosed on at least 2 occasions for a period of at least 3 months, irrespective of the underlying cause and on the basis 1. an estimated or measured glomerular filtration rate \<60 ml/min/1.73 m2 and/or 2. evidence of kidney damage (albuminuria, proteinuria, haematuria after exclusion of urological causes, or structural abnormalities on kidney imaging tests) exclusion criteria: * a subject who refuses to participate in this study
safety and feasibility of early discharge - a prospective and randomized trial of low-risk primary percutaneous coronary intervention (pci) patients

Conditions: Myocardial Infarction

Summary: the purpose of this study is to determine if early hospital discharge (at 48-72 hours), is feasible, safe, cost-effective, and/or improves compliance with medications, positive lifestyle changes and quality-of-life, in low-risk patients with st-elevation myocardial infarction treated with primary percutaneous coronary intervention (primary pci).

patients with acute st-segment elevation myocardial infarction (stemi) have traditionally been hospitalized for at least 5-7 days to monitor for serious complications, including heart failure, arrhythmias, re-infarction and death. with the advent of primary percutaneous coronary intervention (pci) as the treatment of choice for stemi, fewer patients are completing their infarcts and the incidence of complications is decreasing. the zwolle primary pci index is one of several externally validated risk scores that can be used to identify low-risk primary pci patients who can safely be discharged at 48-72 hours. recent reviews have found that a majority of primary pci patients with risk scores that deem them "low-risk" are kept in hospital longer than predicted by these scores. safe-depart is a trial where low-risk primary and rescue pci patients will be randomized either to an intervention arm (early hospital discharge, early outpatient follow-up with a nurse practitioner) or to standard of care (no recommended discharge date, no outpatient follow-up with a nurse practitioner). at 6 weeks time, a blinded research assistant will contact patients and collect data on feasibility, safety, quality-of-life, and cost-effectiveness outcomes.

Eligibility criteria:
inclusion criteria: * patient with st-elevation myocardial infarction (stemi) * treatment with either primary or rescue pci * zwolle risk score \<= 3 exclusion criteria: * developed mi while in hospital for another reason * time from angioplasty to enrollment \> 24 hours

Keywords: stemi primary pci length of stay early discharge
biomechanical properties in intensive care unit (icu) survivors 12-month after discharge

Conditions: Intensive Care (ICU) Myopathy

Summary: intensive care unit (icu) admission is associated with muscle weakness and icu survivors report persevering limitation of physical capacity for years after discharge. limited information is available about the underlying biomechanical properties responsible for this muscle function impairment.


Eligibility criteria:
inclusion criteria: * icu length of stay \> 72 hours * informed consent exclusion criteria: * bmi\>30 * neuromuscular or psychiatric disease

Keywords: icu acquired weakness
prognostic assessment of diastolic and systolic left ventricular function in septic shock

Conditions: Septic Shock; Echocardiography; Diastolic Dysfunction; Hyperkinesia

Summary: sepsis induces a reversible systolic and diastolic cardiac dysfunction. the presence of a left ventricular (lv) diastolic dysfunction during septic shock could favor harmful volume overload. recently, a meta-analysis suggested a negative prognostic role of lv diastolic dysfunction in septic patients (od ratio: 1.82; 95%ci: 1.12 - 2.97; p = 0.02) but its external validity is hampered by the numerous limits and the heterogeneity of the studies. to date, a pathophysiological link between lv diastolic dysfunction associated with septic shock and the water balance (reflecting volume overload) remains to establish. in addition, small size studies reported an excess of mortality in patients with septic shock who were diagnosed with a high cardiac output. however, no large cohort has yet confirmed the negative prognostic role of a hyperkinetic hemodynamic profile at the initial phase of septic shock.

consecutive patients diagnosed with septic shock will be followed daily using echocardiography from day1 (first echocardiography performed within 12h after the diagnosis of septic shock) to day3, after vasopressor discontinuation (day end), and on day28 or at hospital discharge (if occurs before day28). echocardiographic data will be anonymized and stored in dicom format in a dedicated database for independent measurements by an expert in echocardiography blinded from the clinical data of the patients including vital status. vital and biological parameters usually monitored for the management of septic shock will be collected at the time of each echocardiographic assessment. patients' vital status will be collected on day28. the potential influence of lv diastolic dysfunction and lv hyperkinesia on prognosis will be assessed.

Eligibility criteria:
inclusion criteria: * patient hospitalized in icu for septic shock: * documented or highly suspected infection (clinically or microbiologically) * causing an organ failure defined as an acute change in total sofa score ≥ 2 points (baseline sofa score can be assumed to be zero in the absence of pre-existing organ dysfunction) * and low blood pressure (sbp \ 65 mmhg * and lactate level \> 2 mmol/l * patient older than 18 years old affiliated to the french social security * non-opposition of the patient (or of its next-of-kin) to participate in the study exclusion criteria: * ongoing dobutamine or epinephrine infusion * severe left valvular disease (severe stenosis, severe regurgitation ≥ grade 3) * constrictive pericarditis (invalidate the mitral tissue doppler imaging) * pregnant women * patient with estimated life expectancy \< 24h.

Keywords: septic shock echocardiography diastolic dysfunction transthoracic transesophageal hyperkinesia prognosis
central mechanism of manual therapy for low back pain

Conditions: Low Back Pain

Summary: the purpose of this study is to examine the change of nervous system activity before and after spinal manipulation treatment program in people with low back pain.


Eligibility criteria:
inclusion criteria: * diagnosis of subacute low back pain * ability to read and understand english exclusion criteria: * previous low back surgery * severe structural spinal deformity * neurological compromise resulting in current nerve root entrapment * spinal cord compression * tumor * severe spinal instability * severe osteoporosis * psychiatric disease * head trauma * spinal infection * known cardiovascular or metabolic disease * known neurological, neuromuscular or orthopedic problems that might prevent them from participating in manual therapy interventions * pregnancy * mini-mental state examination score \< 25 * body mass index (bmi) \ 30 * pain or paresthesia below the knees * systemic illness known to affect sensation i.e. diabetes * acute and/or chronic pain condition unrelated to lbp
sipuleucel-t based autologous cellular immunotherapy for advanced prostate cancer

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Summary: proposed immunotherapy with an extended course of sipuleucel-t treatment may induce a more robust immune response and improve the anti-cancer efficacy of sipuleucel-t in patients with metastatic castration-resistant prostate cancer (mcrpc).

this open-label, pilot trial aims to evaluate the feasibility of sipuleucel-t given in three doses at weeks 0, 2, and 12-14; and to investigate the changes in immune response in mcrpc patients who are getting an extended course of sipuleucel-t treatment.

Eligibility criteria:
inclusion criteria: 1. men ≥ 18 years of age 2. prostate cancer with history of metastasis 3. candidates for sipuleucel-t treatment are defined as those with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer 4. eastern cooperative oncology group (ecog) performance status of 0 or 1 5. life expectancy of ≥ 6 months exclusion criteria: 1. previously received sipuleucel-t (provenge®) 2. known malignancies other than prostate cancer likely to require treatment within 6 months following registration 3. a requirement for systemic immunosuppressive therapy (\>10mg prednisone daily or equivalent) 4. a history of allergic reactions attributed to compounds of similar chemical or biologic composition to sipuleucel-t or gm-csf 5. any infection requiring antibiotic therapy within 1 week prior to registration

Keywords: antigen presenting cells (apcs) sipuleucel-t (sip-t) granulocyte-macrophage colony-stimulating factor (gm-csf) prostatic acid phosphatase (pap)
a study for prevention of kidney disease in diabetic patients (benedict)

Conditions: Hypertension; Diabetes

Summary: the benedict study is conducted to examine the effects of an ace inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in type 2 diabetic patients.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * hypertension exclusion criteria: * albuminuria (phase a) * non-diabetic renal disease * subject has a hypersensitivity to ace inhibitor, ccb

Keywords: hypertension diabetes trandolapril verapamil albuminuria
efficacy study of shortwave diathermy for the treatment of patients with knee osteoarthritis

Conditions: Osteoarthritis, Knee; Menopause

Summary: the purpose of this study is to determine whether shortwave diathermy is effective in reducing knee pain and increasing function of the patients with knee osteoarthritis.

osteoarthritis (oa) is the most common degenerative joint disease, resulting in significant morbidity and health care expense. it affects more than 60% of western world adults over the age of 65 years. it causes pain and dysfunction in 20% of elderly persons. it can affect any joint containing hyaline cartilage; knee is the most commonly affected joint. there are many strategies for the treatment of knee oa but a curative method has not been found. treatment is therefore aimed to relief symptoms and to prevent further functional deterioration. it is unclear whether any of the treatment modalities is efficacious. shortwave diathermy (swd) is one of deep heat widely applied to alleviate the symptoms associated with oa. the efficacy of swd for the treatment of oa knee is still inconclusive. the outcome of treatment in previous reports varies from null to positive effect. this discrepancy is largely due to the different research methodology, the inadequate sample size, the methods used in outcome assessment, and the treatment protocols. comparison(s): peri- or postmenopausal women with oa knee are randomized into two groups, receiving a course of either therapeutic swd or sham swd. the main outcome measured is the change in western ontario and mcmaster universities osteoarthritis (womac) index.

Eligibility criteria:
inclusion criteria: * peri- or postmenopausal women aged \>50 years * primary knee osteoarthritis exclusion criteria: * inability to walk * severe joint instability * history of previous shortwave diathermy * intra-articular injection within 3 months * metallic implant around knee joint * suspicious of malignancy around knee joint * significant cardiovascular disease * inability to understand how to score the symptoms

Keywords: diathermy short-wave therapy osteoarthritis knee
colonoscopy by videocapsuls versus standard colonoscopy. intra-individual comparison for the subject with a medium or high risk of colorectal cancer.

Conditions: Colorectal Cancer

Summary: colorectal cancer is one of the most frequent and it prognosis is still serious. in france, diagnosis and screening applicated in numerous departements, and now in a path of generalization to the all country, is based on combination of searching blood into bowel movements (haemoccult) for the screening of population with medium risk (age between 50 to 74 years old)and colonoscopy for the screening and diagnosis of pre-cancerous lesions for the patients with a high risk.even if the efficiency of this strategy is proved, searching blood into the bowel movement by haemoccult is still imperfect (a lot of false negative). colonoscopy is not an ideal tool for screening. indeed, its acceptability is not perfect and it constitute an invasive method, with complications, with a compulsory general anesthesia, implicating a high cost. the alternative of a screening method based on a non invasive method is required.


Eligibility criteria:
inclusion criteria: * age between 18 and 80 years * patient able to give his informed consent * no colorectal, intestinal inflammatory, ischemic or evolving infectious pathologies * no signs of stenosis of small intestine or colon * no contraindication to anesthesia * no participation to an other clinical study * patient with and indication to colonoscopy for searching of a colorectal neoplasia during a screening program or * patient for who a endoscopic following is required because of familial cases or personal cases of polyps or colorectal cancer exclusion criteria: * presence of symptoms evocating an occlusive pathology * recent complicated colic diverticulosis * no informed consent * pregnancy or no use of efficient contraception treatment * patient with a pace-maker or others internal medical electronic device * evolved nephric or cardiac insufficiencies * hypersensibility to fleet phospho soda (or one of the excipient), bisacodyl (or one of the excipient), motilium (or one of the excipient) * presence of a prolactinoma

Keywords: patients medium risk asymptomatic between 50 and 74 years old high risk case history of neoplastic colic cancers polyps
glasgow coma scales and general anesthesia

Conditions: Anesthesia Awareness

Summary: the study evaluates the general anesthesia management with bis monitorization in terms of hemodynamic stability, drug concentrations and drug consumption in patients who underwent surgery due to intracranial pathology and who were divided in three different gcs groups.

bis monitoring is mostly used for anesthesia depth and sedation level follow-up, however it can also be used for monitoring consciousness after resuscitation of cases with acute brain injury and cardiac arrest. it is not always possible to monitor and objectively measure the changes in the level of consciousness in clinical practice. therefore, device-based methods have been introduced in monitoring the state of consciousness. bispectral index (bis) monitoring may be preferred in follow up of the state of consciousness in critical patients such as those with acute brain injury, in terms of ease of use, ability to obtain numerical results and continuous monitoring. bis monitoring is mostly used for follow up of anesthesia depth and sedation level, while it can also be applied for monitoring state of consciousness following resuscitation in cases with acute brain injury and cardiac arrest.in this study, we aimed to investigate general anesthesia management performed by bispectral index monitoring in patients who underwent surgery due to intracranial pathology and with different glasgow coma scales.

Eligibility criteria:
inclusion criteria: * 18 and 65 years * asa ii-iii * intracranial surgery exclusion criteria: * patients with additional disease (electrolyte impairment, uremia, etc.), * liver and renal failure affecting consciousness level other than intracranial pathology

Keywords: bispectral index glasgow coma scale intracranial pathology
switch ii early feasibility study: implantable bci to control a digital device for people with paralysis

Conditions: Neurologic Disorder; Paralysis; Paralysis; Stroke; Amyotrophic Lateral Sclerosis; Muscular Dystrophies; Spinal Cord Injury; Stroke, Lacunar; Stroke, Brainstem; Upper Limb Injury; Spinal Muscular Atrophy

Summary: the synchron motor neuroprosthesis (mnp) is intended to be used in subjects with severe motor impairment, unresponsive to medical or rehabilitative therapy and a persistent functioning motor cortex. the purpose of this research is to evaluate safety and feasibility. the mnp is a type of implantable brain computer interface which bypasses dysfunctional motor neurons. the device is designed to restore the transmission of neural signal from the cerebral cortex utilized for neuromuscular control of digital devices, resulting in a successful execution of non-mechanical digital commands.


Eligibility criteria:
inclusion criteria: 1. severe motor impairment 2. able to give consent 3. appropriate candidate for neurointerventional procedure 4. able and willing to access all clinical testing and not impeded by geographical location 5. proficient in english 6. have a study partner exclusion criteria: 1. active condition resulting in immunosuppression 2. unsuitable for general anaesthetic 3. anaphylactic allergy to contrast media 4. allergy to nickel 5. history of pulmonary embolism 6. history of recent deep vein thrombosis 7. psychiatric or psychological disorder 8. no study partner or caregiver 9. unable to provide evidence of covid vaccination
effectiveness study low-dose naltrexone versus arv's for hiv+

Conditions: HIV Seropositivity

Summary: in the vast majority of those infected with hiv virus who are untreated, there is deterioration in immune health over a period of months or years inevitably leading to full-blown aids and demise. treatment with arv's stop or slow down this deterioration if started before a certain degree of progression occurs and has saved millions of lives. the investigators' study hypothesis is that effectiveness of a very low dose of an fda-approved medication, naltrexone hydrochloride, (low-dose naltrexone, or ldn) will compare favorably to arv's to prevent progression of hiv+ toward immune deterioration and full-blown aids.

the ldn (low-dose naltrexone) vs arv (anti-retroviral drugs) effectiveness study in mali sponsored by the ojai foundation in california-usa is a clinical research study endorsed and approved by the malian government. naltrexone hydrochloride is a generic, fda-approved since 1998 drug, an opioid antagonist that has clinically shown immune enhancing/modulating qualities in very low dosage and may offer an alternative to arv drugs that is effective, non-toxic, easily available, inexpensive, with simple once-daily at bedtime administration. ldn capsules must be created by compounding pharmacists to get these ultra-small doses. due to toxicity of current arv drugs and need for special medical management young hiv infected children are largely neglected particularly in developing countries; ldn can also be made available in a transdermal cream for infants and children who are hiv infected.

Eligibility criteria:
inclusion criteria: * hiv-1 infected * cd4 count over 350 (arm 1/group 1) * cd4 count over 200 and on arv's (arms 2,3/groups 2,3) * age between 18 \& 60 * males or females exclusion criteria: * hiv-1 seronegative * hiv-2 infected * cd4 count lower than 200 * patients under age 18 * those refusing to be in study * pregnant or breast-feeding women * patients under immuno-suppressor therapy * those with renal or hepatic dysfunction * malaria or tuberculosis